Nigel Titchener-Hooker, Ph.D., Professor, Biochemical Engineering, University College London
Professor Nigel Titchener-Hooker heads the Department of Biochemical Engineering at UCL where he directs the Centre for Innovative Manufacturing of Emerging Macromolecular Therapies. The Centre goals is to accelerate the development of biopharmaceutical processes and involves collaboration with an international consortium of 25 companies and valued at over £30M As the first director of the Engineering Doctorate Centre for Bioprocess Leadership he managed a portfolio of over 60 doctorate programmes with companies spanning the whole breadth of the biotech industry from small to macromolecular processing and to the nascent regenerative medicines area.
Nigel has held consultancies with a broad range of international companies and serves on the editorial board of key peer-reviewed journals. He was elected a Fellow of the Royal Academy of Engineering in 2008 in recognition of his pioneering work on biopharmaceuticals manufacturing. He is a Fellow of the Institution of Chemical Engineers. He was Chair of the Board of the prestigious ACS-supported Recovery of Biological Products conference series from 2010-12.
David W. Wood, Ph.D., Associate Professor, Chemical & Biomolecular Engineering, The Ohio State University
David Wood is an Associate Professor of Chemical and Biomolecular Engineering at The Ohio State University. He received his undergraduate degree from the Caltech in 1990 with a double major in Chemical Engineering and Molecular Biology. He then spent one year working in large-scale bioprocess development, followed by two years at Amgen in Neupogen® manufacturing. After this, he returned for his PhD at Rensselaer Polytechnic Institute, where he was co-advised by Georges and Marlene Belfort. He completed his PhD in 2001 and joined the faculty at Princeton University, where he continued his work in protein engineering and bioprocess design, and eventually developed a series of protein purification methods based on self-cleaving tags. During his time at Princeton, he received the NSF Career Award, as well as two patents on intein-based technologies. His work on protein purification and biosensingis continuing at Ohio State University, and has been funded by the NSF, NIH, US Army, and a variety of private companies and foundations.
Carlo Zambonelli, Ph.D., Lab Head, Protein Characterization, Novartis Vaccines & Diagnostics, Inc.
Carlo Zambonelli obtained a Ph.D in 2000 from Milano University, Italy. He completed his postdoctoral training in biophysics andenzymology in the U.S. at Boston College and Harvard University. In 2009, he joined Novartis Vaccines and Diagnostics (NVD) in Cambridge, MA, where his work focused on the design, purification, and characterization of HIV antigens. After 11 years in the U.S., he recently moved back to Italy to join NVD in Siena where he is Lab Head for Protein Characterization and his main role is to lead the analytical and functional characterization of bacterial antigens.
Heidi Roschitzki-Voser, Ph.D., Senior Scientist, Biochemistry Institute, University of Zurich
Heidi Roschitzki-Voser is currently a postdoctoral fellow in the biochemistry institute at the University of Zurich, Switzerland. In her studies, she has focused on the heterologous expression and purification of proteases and their kinetic and structural characterization. Heidi Roschitzki-Voser did a bachelor of dietetics and worked as a dietitian before she did her master in biochemistry at the University of Zurich and her PhD at the institute of biochemistry.
Thomas Magliery, Ph.D., Assistant Professor, Chemistry & Biochemistry, The Ohio State University
Thomas Magliery is a member of the: Ohio State Biochemistry Program (OSBP); Biophysics Graduate Program; Microbiology Graduate Program; Chemistry-Biology Interface Training Program (CBIP); Cellular, Molecular, and Biochemical Sciences Program (CMBP). He was an NIH Postdoctoral Fellow in Molecular Biophysics & Biochemistry at Yale University He received his Ph.D. in Chemistry from the University of California, Berkeley in 2001, and his A.B. in Chemistry from Kenyon College in 1996.
Andreas Anton, Ph.D., Director, Contract Development, Scil Proteins GmbH
Andreas Anton is currently Director of the Contract Development unit at Scil Proteins. He is responsible for the complete development of production processes for external and internal projects. This includes the development and optimization of production strains, upstream and downstream processes, folding procedures, the establishment and qualification of analytical methods as well as transfer of production processes into GMP environments. Since Andreas joined Scil Proteins in 2002 as a research scientist for development of new manufacturing technologies he developed e.g. a proprietary expression system for antibiotic free fermentation in E. coli and established scalable in vitro folding procedure for the application in upscaling and commercial manufacturing.
Alexei Yeliseev, Ph.D., Staff Scientist, LMBB, NIH/ NIAAA
Alexei A. Yeliseev, Ph.D. Staff Scientist, National Institute on Alcoholism and Alcohol Abuse, National Institutes of Health
M.S. Chemistry, M.V. Lomonosov Moscow State University, 1981 Ph.D. Biochemistry, A.N. Bakh Institute of Biochemistry, Russian Academy of Sciences, 1987 Post-doctoral training: -Alexander von Humboldt Fellowship at Phillips-University in Marburg, Germany (1989-1992); -Academic exchange fellowship from the Royal Society at the University Chemical Laboratories in Cambridge, UK (1993) -Senior Fellow at the University of Texas-Houston Medical School, USA (1993-1999). Senior Research Scientist with Hoffmann-La Roche (Nutley, NJ) (1999-2001) Senior Scientist at Kosan Biosciences, Inc (Hayward, CA) (2001-2003) Staff Scientist, head of GPCR expression and biochemistry group at the National Institute on Alcoholism and Alcohol Abuse, National Institutes of Health (Bethesda, USA) (2003-present) Services: member of editorial board of Protein Expression and purification and Journal of Receptor, Ligand and Channel Research.
Mario Lebendiker, Ph.D., Head, Protein Purification Facility, Wolfson Centre for Applied Structural Biology, The Hebrew University of Jerusalem
Dr. Mario Lebendiker is in charge of the Protein Purification Facilities at the Wolfson Centre for Applied Structural Biology, The Hebrew University of Jerusalem. He is actively involved in many collaborations for structural and biochemical studies within the Hebrew University, others Universities in Israel, as well as with biotech and pharmaceutical companies. Dr. Lebendiker received a PhD in Biochemistry in 1982 from the Animal Virology Center (CEVAN), in Buenos Aires University, Argentina. Together with many other laboratories, he found the Protein Production and Purification Partnership in Europe (P4EU) network; a platform for the exchange of information, know-how and materials between core facility labs in the field of protein expression and purification.
Karin Crowhurst, Ph.D., Assistant Professor, Chemistry and Biochemistry, California State University
Karin Crowhurst received her PhD in Biochemistry and Biomolecular Structurefrom the University of Toronto in 2003. Her thesis project focused on obtaining atomic-resolution evidence for residual, semi-stabilized tertiary interactions within the unfolded state of the SH3 domain of Drosophila Drkthat could advance our understanding of fundamental mechanisms of protein folding and stability. She next pursued a postdoctoral position in the computational protein design lab of Dr. Stephen Mayo at Caltech in Pasadena, working to understand the biophysical basis of the stability of proteins designed in the lab. In 2007 Karin started herfaculty position in the Department of Chemistry and Biochemistry at California State University Northridge (CSUN). Her current research focuses on using NMR spectroscopy to study internal protein motions within two families of signaling proteins and how these motions influence the selectivities of these proteins for their binding targets.
Susan Daniel, Ph.D., Assistant Professor, Chemical & Biomolecular Engineering, Cornell University
Susan Daniel received her PhD from Lehigh University in the Department of Chemical Engineering (2005). She specialized in the area of surface science, studying the effect of surface wettability gradients on the motion of liquid droplets when they coalesce with other droplets or are subjected to vibration. In 2005, Dr. Daniel joined Texas A&M University, Department of Chemistry, as a Postdoctoral Associate. There she expanded her expertise to the area of biological surface science. Specifically, Dr. Daniel used solid-supported lipid bilayers as mimics of the cell membrane for the development of biosensors and microfluidic assays for interrogating biological phenomena. In 2007, Dr. Daniel joined Cornell University as an Assistant Professor of Chemical and Biomolecular Engineering. The general theme of her research group is the study of transport and dynamics at biological interfaces.
Ario de Marco, Ph.D., Head, Biochemistry Unit, Consortium for Genomic Technologies (COGENTECH)
Ario de Marco was responsible for the Protein Production Facilities at EMBL (Germany) and IFOM-IEO (Italy). At present, he is in charge of the Therapeutic Recombinant Antibody Platform at the Institut Curie (France). His group uses large pre-immune libraries of single-domain antibodies for identifying binders that recognize specific markers of cell sub-types and can be applied in diagnosis and therapy. Beside the discovery activity, the group is active in developing approaches for optimizing the antibody production and their transformation in reagents tailored for different in vitro and in vivo applications.
Jean François Depoisier, Head, Downstream Processing, NovImmune
Jean François Depoisier is Head of downstream processing at NovImmune a Biotech SME based in Geneva, Switzerland. Jean François joined NovImmune in 2008 and is responsible for leading the purification process development group. Jean Franç-body purification platform process. Prior to joining NovImmune, he worked at SGS M-Scan from 2003 as a study director and at Geneprot Inc. from 2001 where he was in charge of the Biochemistry Lab. He worked at Pierre Fabre from 1992 in Purification department. Jean-Franlkois has overseen the increase of purification capacities and implementation of disposable technologies, as well as the design of the bispecific çois obtained his Bachelor’s degree in biology at the University of Lyon in 1989.
Ruby Casareno, Ph.D., Principal Scientist, BioProcess Development, Seattle Genetics, Inc.
Ruby Casareno received her Ph.D. in Chemistry from The Ohio State University. She has twelve years of industrial experience in Biologics Process Development, Scale Up/Down, Technology Transfer, and Manufacturing Oversight.
Suparna Mundodi, Ph.D., Global Product Manager, Global Marketing, Rainin Instrument, LLC
Suparna Mundodi is a Product Marketing Manager at Rainin Instruments, Mettler-Toledo company, Oakland, CA where she is responsible for delivering effective strategic and tactical marketing solutions for life science products. In 2012, she has successfully created a radically new market for her company by introducing PureSpeed Protein Purification System which offers a new process for IP/ChIP, purifying antibodies and recombinant proteins using affinity resin in a pipette tip. Prior to joining Rainin Instruments, Suparna worked in Sales and Marketing group at Bio-Rad Labs, Hercules, CA and as a Bioinformatics Scientist at Stanford University, CA. She received her Ph.D in Biochemistry from Oklahoma State University and post-doctoral fellowship from Molecular biology division at Samuel Roberts Noble Foundation where she characterized genes responsible for hypersensitive response to fungal and bacterial pathogens. Suparna has extensive teaching experience having taught multiple bioinformatics courses at University of California schools.
Megan C. Thielges, Ph.D., Assistant Professor, Department of Chemistry, Indiana University
Megan Thielges is an Assistant Professor in the Department of Chemistry at Indiana University. She received her B.S. in Biochemistry at Arizona State University (Tempe, AZ) in 2003 and her Ph.D. in biophysics in 2009at The Scripps Research Institute (La Jolla, CA). She went on to a NSRA funded postdoctoral fellowship at Stanford University before joining the faculty of Indiana University in the summer of 2012. Her research focuses on applying and further developing modern multidimensional infrared spectroscopy in combination with chemical and biological methods toward understanding biological systems. Her group aims to generate residue-specific descriptions of the structural dynamics of proteins, delineate their contributions to function, and assess the role of dynamics in protein evolution. A central interest of her group is biological molecular recognition, particularly involving proteins with intrinsically disordered regions.
Evelina Angov, Ph.D., Microbiologist, Military Malaria Research Program, Malaria Vaccine Branch, Walter Reed Army Institute of Research (WRAIR)
Evelina Angov, M.S., Ph.D., received her M.S. and Ph.D. degrees from the University of Maryland, College Park in Biochemistry. She completed a Post Doctoral Fellowship in the Genetics and Biochemistry Branch of NIDDK, NIH, Bethesda, MD. She currently serves as the Chief of the Laboratory of Molecular Parasitology at the Walter Reed Army Institute of Research, Malaria Vaccine Branch. She works on projects to develop recombinant P. falciparum malaria proteins for their use as malaria vaccine candidates as well as to evaluate immune responses induced by these vaccines. In conjunction with the development of these target antigens, she has worked to establish standardized immunological assays to characterize humoral and cellular immune responses. Recently, her laboratory has evaluated several novel platforms of expression and delivery of malaria vaccine candidates as a means to improve immunological responses.
David O’Connell, Ph.D., Senior Scientist, School of Medicine, Conway Institute of Biomolecular & Biomedical Research, University College Dublin
Dr David O’Connell is a Senior Research Scientist in the School of Medicine at University College Dublin whose research primarily focuses on high throughput protein:protein interaction studies, with a particular emphasis on calcium binding proteins. Previously Dr O’Connell trained in the Marks lab in the University of California at San Francisco specialising in phage display of human antibodies and humanisation of murine antibodies. More recently Dr O’Connell has spent a number of years on method development for high throughput characterisation of interactions using biophysical methods including SPR and ITC publishing a number of papers in this area with calcium binding protein interactomes. Dr O’Connell has filed a series of patents in the area of protein purification technologies and is collaborating major biopharma companies in this area.